Unraveling the Allosteric Mechanism of Serine Protease Inhibition by an Antibody

Structure

Volumn 17, Issue 12, 2009, Pages 1614-1624

  Ganesan, Rajkumar ^a   Eigenbrot, Charles ^a   Wu, Yan ^a   Liang, Wei Ching ^a   Shia, Steven ^a   Lipari, Michael T ^a   Kirchhofer, Daniel ^a  

^a GENENTECH INC   (United States)

Author keywords

PROTEINS

Indexed keywords

ENZYME ANTIBODY; HEPATOCYTE GROWTH FACTOR ACTIVATOR; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANTIGEN BINDING; ARTICLE; BINDING SITE; CATALYSIS; CONFORMATIONAL TRANSITION; ENZYME INHIBITION; MOLECULAR MECHANICS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; AMINO ACID SEQUENCE; ANTIBODIES; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID; SERINE PROTEASES; SERINE PROTEINASE INHIBITORS;

EID: 71049189254     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.str.2009.09.014     Document Type: Article

References (60)

1. Adams G.P., and Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23 (2005) 1147-1157
2. Barrett A.J., Rawlings N.D., and Woessner J.F. Handbook of Proteolytic Enzymes (1998), Academic Press, San Diego
3. +-induced Enhancement of the Intrinsic Factor VIIa Activity. J. Biol. Chem. 283 (2008) 25863-25870
4. Bock P.E., Panizzi P., and Verhamme I.M. Exosites in the substrate specificity of blood coagulation reactions. J. Thromb. Haemost. 5 Suppl 1 (2007) 81-94
5. CCP4 (Collaborative Computational Project, Number 4). The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. D50 (1994) 760-763
6. Changeux J.P., and Edelstein S.J. Allosteric mechanisms of signal transduction. Science 308 (2005) 1424-1428
7. del Sol A., Tsai C.J., Ma B., and Nussinov R. The origin of allosteric functional modulation: multiple pre-existing pathways. Structure 17 (2009) 1042-1050
8. Di Cera E. A structural perspective on enzymes activated by monovalent cations. J. Biol. Chem. 281 (2006) 1305-1308
9. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2 (2002) 161-174
10. Eigenbrot C., and Kirchhofer D. New Insight into How Tissue Factor Allosterically Regulates Factor VIIa. Trends Cardiovasc. Med. 12 (2002) 19-26
11. Farady C.J., Egea P.F., Schneider E.L., Darragh M.R., and Craik C.S. Structure of an Fab-protease complex reveals a highly specific non-canonical mechanism of inhibition. J. Mol. Biol. 380 (2008) 351-360
12. Fenton A.W. Allostery: an illustrated definition for the 'second secret of life'. Trends Biochem. Sci. 33 (2008) 420-425
13. Friedrich R., Panizzi P., Fuentes-Prior P., Richter K., Verhamme I., Anderson P.J., Kawabata S.-I., Huber R., Bode W., and Bock P.E. Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature 425 (2003) 535-539
14. Goodey N.M., and Benkovic S.J. Allosteric regulation and catalysis emerge via a common route. Nat. Chem. Biol. 4 (2008) 474-482
15. Gunasekaran K., Ma B., and Nussinov R. Is allostery an intrinsic property of all dynamic proteins?. Proteins 57 (2004) 433-443
16. Hardy J.A., and Wells J.A. Searching for new allosteric sites in enzymes. Curr. Opin. Struct. Biol. 14 (2004) 706-715
17. Hardy J.A., and Wells J.A. Dissecting an allosteric switch in caspase-7 using chemical and mutational probes. J. Biol. Chem. 284 (2009) 26063-26069
18. Hardy J.A., Lam J., Nguyen J.T., O'Brien T., and Wells J.A. Discovery of an allosteric site in the caspases. Proc. Natl. Acad. Sci. USA 101 (2004) 12461-12466
19. Hauske P., Ottmann C., Meltzer M., Ehrmann M., and Kaiser M. Allosteric regulation of proteases. ChemBioChem 9 (2008) 2920-2928
20. Hedstrom L. Serine protease mechanism and specificity. Chem. Rev. 102 (2002) 4501-4524
21. Herter S., Piper D.E., Aaron W., Gabriele T., Cutler G., Cao P., Bhatt A.S., Choe Y., Craik C.S., Walker N., et al. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem. J. 390 (2005) 125-136
22. Hooper N.M. Proteases in Biology and Medicine. Essays in Biochemistry (2002), Portland Press, London
23. Hopfner K.P., Lang A., Karcher A., Sichler K., Kopetzki E., Brandstetter H., Huber R., Bode W., and Engh R.A. Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding. Structure 7 (1999) 989-996
24. Huber R., and Bode W. Structural basis of the activation and action of trypsin. Acc. Chem. Res. 11 (1978) 114-122
25. Huntington J.A. How Na+ activates thrombin-a review of the functional and structural data. Biol. Chem. 389 (2008) 1025-1035
26. Kabat E.A., Wu T.T., Perry H.M., Gottesman K.S., and Foeller C. Sequences of proteins of immunological interest. Fifth Edition (1991), National Institutes of Health, Bethesda, Maryland
27. Kataoka H., Miyata S., Uchinokura S., and Itoh H. Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev. 22 (2003) 223-236
28. Kawaguchi M., Orikawa H., Baba T., Fukushima T., and Kataoka H. Hepatocyte growth factor activator is a serum activator of single-chain precursor macrophage-stimulating protein. FEBS J. 276 (2009) 3481-3490
29. Kirchhofer D., Peek M., Li W., Stamos J., Eigenbrot C., Kadkhodayan S., Elliott J.M., Corpuz R.T., Lazarus R.A., and Moran P. Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J. Biol. Chem. 278 (2003) 36341-36349
30. Krauss G. Biochemistry of Signal Transduction and Regulation (2003), Wiley and Sons, New York 89-114
31. Lee G.M., and Craik C.S. Trapping moving targets with small molecules. Science 324 (2009) 213-215
32. Lee C.V., Liang W.C., Dennis M.S., Eigenbrot C., Sidhu S.S., and Fuh G. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J. Mol. Biol. 340 (2004) 1073-1093
33. Lee C.V., Sidhu S.S., and Fuh G. Bivalent antibody phage display mimics natural immunoglobulin. J. Immunol. Methods 284 (2004) 119-132
34. Liang W.C., Dennis M.S., Stawicki S., Chanthery Y., Pan Q., Chen Y., Eigenbrot C., Yin J., Koch A.W., Wu X., et al. Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J. Mol. Biol. 366 (2007) 815-829
35. Luttun A., Dewerchin M., Collen D., and Carmeliet P. The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies. Curr. Atheroscler. Rep. 2 (2000) 407-416
36. McCoy A.J., Grosse-Kunstleve R.W., Storoni L.C., and Read R.J. Likelihood-enhanced fast translation functions. Acta Crystallogr. D Biol. Crystallogr. 61 (2005) 458-464
37. Miyazawa K., Shimomura T., Kitamura A., Kondo J., Morimoto Y., and Kitamura N. Molecular cloning and sequence analysis of the cDNA for a human serine protease reponsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J. Biol. Chem. 268 (1993) 10024-10028
38. Monod J. Chance and Necessity: Essay on the Natural Philosophy of Modern Biology (1971), Knopf, New York
39. Olsen O.H., and Persson E. Cofactor-induced and mutational activity enhancement of coagulation factor VIIa. Cell. Mol. Life Sci. 65 (2008) 953-963
40. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. In: Macromolecular Crystallography Part A. Methods Enzymol. 276 (1997) 307-326
41. Parr C., and Jiang W.G. Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int. J. Oncol. 19 (2001) 857-863
42. Pellicena P., and Kuriyan J. Protein-protein interactions in the allosteric regulation of protein kinases. Curr. Opin. Struct. Biol. 16 (2006) 702-709
43. Perutz M.F. Stereochemistry of cooperative effects in haemoglobin. Nature 228 (1970) 726-739
44. Peterson J.R., and Golemis E.A. Autoinhibited proteins as promising drug targets. J. Cell. Biochem. 93 (2004) 68-73
45. Raddatz R., Schaffhauser H., and Marino M.J. Allosteric approaches to the targeting of G-protein-coupled receptors for novel drug discovery: a critical assessment. Biochem. Pharmacol. 74 (2007) 383-391
46. Rawlings N.D., Morton F.R., Kok C.Y., Kong J., and Barrett A.J. MEROPS: the peptidase database. Nucleic Acids Res. 36 (2008) D320-D325
47. Segel I. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems (1993), Wiley, New York 161-226
48. Shia S., Stamos J., Kirchhofer D., Fan B., Wu J., Corpuz R.T., Santell L., Lazarus R.A., and Eigenbrot C. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B. J. Mol. Biol. 346 (2005) 1335-1349
49. Shimomura T., Miyazawa K., Komiyama Y., Hiraoka H., Naka D., Morimoto Y., and Kitamura N. Activation of hepatocyte growth factor by two homologous proteases, blood-coagulation factor XIIa and hepatocyte growth factor activator. Eur. J. Biochem. 229 (1995) 257-261
50. Sohn J., Grant R.A., and Sauer R.T. Allosteric Activation of DegS, a Stress Sensor PDZ Protease. Cell 131 (2007) 572-583
51. Spraggon G., Hornsby M., Shipway A., Tully D.C., Bursulaya B., Danahay H., Harris J.L., and Lesley S.A. Active site conformational changes of prostasin provide a new mechanism of protease regulation by divalent cations. Protein Sci. 18 (2009) 1081-1094
52. Swain J.F., and Gierasch L.M. The changing landscape of protein allostery. Curr. Opin. Struct. Biol. 16 (2006) 102-108
53. Tereshko V., Uysal S., Koide A., Margalef K., Koide S., and Kossiakoff A.A. Toward chaperone-assisted crystallography: protein engineering enhancement of crystal packing and X-ray phasing capabilities of a camelid single-domain antibody (VHH) scaffold. Protein Sci. 17 (2008) 1175-1187
54. Tsai C.J., Del Sol A., and Nussinov R. Protein allostery, signal transmission and dynamics: a classification scheme of allosteric mechanisms. Mol. Biosyst. 5 (2009) 207-216
55. Turk B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 5 (2006) 785-799
56. Vajpai N., Strauss A., Fendrich G., Cowan-Jacob S.W., Manley P.W., Grzesiek S., and Jahnke W. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J. Biol. Chem. 283 (2008) 18292-18302
57. Wells C.M., and Di Cera E. Thrombin is a Na(+)-activated enzyme. Biochemistry 31 (1992) 11721-11730
58. Wu Y., Eigenbrot C., Liang W.-C., Stawicki S., Shia S., Fan B., Ganesan R., Lipari M.T., and Kirchhofer D. Structural insight into distinct mechanisms of protease inhibition by antibodies. Proc. Natl. Acad. Sci. USA 104 (2007) 19784-19789
59. Xu Z., Horwich A.L., and Sigler P.B. The crystal structure of the asymmetric GroEL-GroES-(ADP)7 chaperonin complex. Nature 388 (1997) 741-750
60. Yu E.W., and Koshland Jr. D.E. Propagating conformational changes over long (and short) distances in proteins. Proc. Natl. Acad. Sci. USA 98 (2001) 9517-9520